AI assistant
RELMADA THERAPEUTICS, INC. — Director's Dealing 2021
May 5, 2021
34465_dirs_2021-05-05_9bb421a2-a646-4c4f-9222-5774bd896689.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2021-05-03
Reporting Person: CASAMENTO CHARLES J (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-03 | Common Stock | S | 3000 | $38.2157 | Disposed | 9950 | Direct |
Footnotes
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020.
F2: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
F3: Sales prices range from $37.94 to $38.94 per share, inclusive.